Onchilles Pharma

[Onchilles Pharma @onchilles]

Onchilles Pharma will present the translational design of OP-NEU-101, its Phase 1/2 first-in-human study of N17350, at #ESMO26. The study is designed to assess ELANE pathway engagement, direct tumor killing, and systemic anti-tumor immunity.

https://t.co/nCKe1MYt5u

[Onchilles Pharma @onchilles]

Onchilles has dosed the first patient in a Phase 1/2 trial of N17350, our lead tumor-directed ELANE pathway therapeutic, to evaluate its potential to selectively kill cancer cells in advanced solid tumors while preserving and not suppressing immune cells.

https://t.co/FruOaetRdX

[Onchilles Pharma @onchilles]

Onchilles Pharma will present a trial in progress poster at the 2026 ASCO Annual Meeting highlighting OP-NEU-101, a Phase 1/2 study of intratumoral N17350 in advanced solid tumors.

More #ASCO26 details: https://t.co/mlol5cttBp

[Onchilles Pharma @onchilles]

New NEU-002 data presented at #AACR26 support a systemic approach built on the ELANE pathway, intended to kill tumor cells while sparing immune cells. Program leads showed anti-tumor activity after both IV and IP administration.

https://t.co/bOBw1xLcPb

[Onchilles Pharma @onchilles]

We will present new preclinical data at #AACR26 demonstrating anti-tumor activity of our ELANE pathway therapeutic NEU-002, extending the platform into systemic solid tumor targeting, as we approach development candidate selection for this program.

https://t.co/eh9T8q0hP0

[Onchilles Pharma @onchilles]

For decades, we’ve accepted a tradeoff: kill the tumor or preserve the immune system.

Not anymore.

On this podcast, our co-founders discuss how our therapeutics targeting the ELANE pathway can pair selective cancer killing with immune activation.

https://t.co/AxryqxI7Pw

[Onchilles Pharma @onchilles]

Onchilles will present and participate in 1-on-1 meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference.

For details and scheduling information, see the release: https://t.co/Rn6bPNI2aQ

[Onchilles Pharma @onchilles]

Onchilles Pharma Announces IND Clearance for N17350, Advancing the First Next-Generation Cytotoxic Therapeutic Leveraging the #ELANE Pathway into the Clinic

Read the release for more: https://t.co/PvEhE9TlvN

[Onchilles Pharma @onchilles]

Onchilles Pharma today announced peer-reviewed preclinical data for N17350, a tumor-directed biologic that leverages the #ELANE pathway to selectively kill cancer cells while preserving immune function, alongside new financing and a key clinical advisor.

https://t.co/TlwxzO6KQb

[Onchilles Pharma @onchilles]

New data presented at #AACR25 show our lead therapeutic candidate, N17350, delivers potent, selective tumor killing while preserving immune function—with the potential to overcome chemotherapy-resistant disease.

Read the release: https://t.co/KNY6i49ZMr

#ELANEpathway #ELANE

[Onchilles Pharma @onchilles]

We're unveiling at #AACR25 new preclinical data for the next-generation cytotoxic therapeutic, N17350, which leverages the #ELANE pathway and has the potential to selectively kill #cancer and stimulate the immune system.

https://t.co/QtHuPKnpm4

[Onchilles Pharma @onchilles]

Thrilled to welcome Dr. Lev Becker as CSO and Emily Roberts-Thomson as SVP of Development Operations! Their leadership will drive our pan-cancer therapeutics targeting the #ELANE pathway into clinical trials.

Learn more: https://t.co/VDqs1gzsHg

#immunotherapy #cancer

[Onchilles Pharma @onchilles]

Today we announced new preclinical data presented at #SITC24 for the NEU-002 program – targeting the #ELANE pathway through systemic delivery, for potent and selective cancer killing with the potential to treat a wide range of cancers.

https://t.co/LYyemHGq4l

[Onchilles Pharma @onchilles]

Today we announced the presentation of new preclinical data at #SITC24 for our NEU-002 program, leveraging the #ELANE pathway, a novel innate immune MOA for potent and selective cancer killing with the potential to treat a wide range of cancers.

https://t.co/evmkolaWz5

[Onchilles Pharma @onchilles]

Our cofounder @LevBecker chatted with @Pharmashot about the excitement around our #AACR24 data, the difference between N17350 and N17465, and details for our upcoming #clinicaltrial.

Read the Q&A here: https://t.co/MfsZdq9S1s

[Onchilles Pharma @onchilles]

Today in #SanDiego we gave a talk titled, “N17350: a novel therapeutic modality that selectively kills #cancer cells and induces potent anti-tumor immunity to eradicate tumors.”

If you missed it, read our recent data release: https://t.co/JjUwJffIOq

[Onchilles Pharma @onchilles]

Our cofounders chatted with @SDbusiness about our recent #AACR24 data showing our lead drug candidate works across many #cancer types to kill tumor cells but leave healthy cells alone – as well as how our upcoming #clinicaltrial could quickly yield data.

https://t.co/JaHVAZzStO

[Onchilles Pharma @onchilles]

We presented at #AACR24 new preclinical data for tumor-directed N17350 and systemically delivered N17465 demonstrating the potential for potent and tumor-selective treatment for a wide range of cancers.

Read the release here: https://t.co/JjUwJffIOq

#cancer #innatepathway

[Onchilles Pharma @onchilles]

We're unveiling at #AACR24 preclinical data on systemically delivered N17465 in an oral presentation and new preclinical data for tumor-directed N17350. Both leverage a novel innate immune MOA and have the potential to treat a wide range of cancers.

https://t.co/QpZMBjv93a

[Onchilles Pharma @onchilles]

In this Q&A with @DrugTargetRev, our cofounder Dr. Lev Becker shares more about how N17350 selectively and potently kills cancer cells irrespective of their genetics and anatomical origin, mobilizes adaptive immunity, and avoids resistance mechanisms.

https://t.co/olBshgdumy